Site Editor
Soo Park, MD
Soo Park, MD
Posted: Tuesday, October 25, 2022
Treatment of locally advanced or inoperable metastatic basal cell carcinoma currently centers on Hedgehog inhibitors (vismodegib or sonidegib). A recent article published in the Journal of the European Academy of Dermatology and Venereology presented findings from a multicenter cohort study aimed to retrospectively analyze the efficacy and safety of treatment with vismodegib in patients with locally advanced or metastatic disease. Izabella Lasińska, MD, PhD, of the Heliodor Święcicki Clinical Hospital, Poznań University of Medical Sciences, Poland, and colleagues found that the overall survival rate 1 year after treatment with vismodegib was 86%. They also reported the treatment was well tolerated, and the safety profile was consistent with other studies.
A total of 108 patients with basal cell carcinoma were included in this study. Drug efficacy was evaluated by progression-free survival, overall survival, overall response rate, and disease control rate. The duration of treatment was calculated as the time from the first dose to treatment discontinuation for any reason, and an overall response rate was recorded as a complete or partial response. The Common Terminology Criteria for Adverse Events version 5.0 were used to classify the severity of reported adverse events.
Overall findings revealed the median duration of treatment was 14 months (range, 1–94 months). Additionally, the median progression-free survival was 30.5 months (95% confidence interval [CI] = 24.8–36.3 months), and the median overall survival was 41.5 months (95% CI = 31.6–51.3 months). The toxicity profiles revealed that many patients experienced at least one treatment-emergent adverse event, which was consistent with results reported in other clinical trials.
Disclosure: For full disclosures of the study authors, visit wiley.com.
Journal of the European Academy of Dermatology and Venereology
JNCCN Spotlights
